Shopping Cart
- Remove All
Your shopping cart is currently empty
(49)
By Tag- C-His-Avi
- N-His(6)
- N-GST(2)
- C-Myc(1)
- N-10xHis(1)
- N-His-Avi(1)
Filter
Applied FilterClear all
By Tag By Expression System- HEK293 Cells(37)
- E. coli(21)
- Baculovirus Insect Cells(1)
By Species- Human(57)
- HCV(1)
- Salmonella enteritidis(1)
By SPR-compatible Buffer- Ready-to-use(48)
- Buffer exchange required(10)
- Buffer-exchangeable(1)
Filter
Search Result
Results for "
ns 3
" in TargetMol Product Catalog- Inhibitors & Agonists11
- Peptide Products1
- Natural Products1
- Recombinant Protein59
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPU-00001
KRAS Protein, Human, Recombinant (G12S, GST) is expressed in E. coli expression system with GST tag. The accession number is P01116.
Inquiry
CompareNS3
TMPY-00323
HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3 NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. One of the HCV proteases, NS3-4A serine protease, is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein) and is responsible for cleavage at four sites of the HCV polyprotein.
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04113
KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-04116
KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06056
KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2.
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06138
KRAS Protein, Human, Recombinant (61Q, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 21.9 kDa and the accession number is P01116-2.
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
TMPY-06345
KRAS Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with His and Avi tag. The predicted molecular weight is 23.78 kDa and the accession number is P01116-2.
- Inquiry Price
Size
QTY
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01399
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01400
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01401
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01402
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01403
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01404
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01407
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01408
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01427
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01428
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01429
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01430
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01431
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01432
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01433
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01434
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
SPR-compatible buffer
CompareRASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2
TMPK-01435
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Inquiry Price
Size
QTY
Go to page 1
Page of 2
Product Comparison
| Product |
|---|
| Bioactive |
| Species |
| Expression System |
| Tag |
| Accession Number |
| Amino Acid |
| Construction |
| Molecular Weight |
| Endotoxin |
| Formulation |
| Reconstitution |
| Stability & Storage |
| Shipping |
| Research Background |
| Size |
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.